Efficacy and Safety of Dolutegravir With Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy oIMPAACT 2010/VESTEDTHORN: A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial

被引：0
|
作者：
Aquino, Marcella
机构：
来源：
PEDIATRICS | 2021年 / 148卷
关键词：
D O I：
10.1542/peds.2021-053843YYYY
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
    Lockman, Shahin
    Brummel, Sean S.
    Ziemba, Lauren
    Stranix-Chibanda, Lynda
    McCarthy, Katie
    Coletti, Anne
    Jean-Philippe, Patrick
    Johnston, Ben
    Krotje, Chelsea
    Fairlie, Lee
    Hoffman, Risa M.
    Sax, Paul E.
    Moyo, Sikhulile
    Chakhtoura, Nahida
    Stringer, Jeffrey S. A.
    Masheto, Gaerolwe
    Korutaro, Violet
    Cassim, Haseena
    Mmbaga, Blandina T.
    Joao, Esau
    Hanley, Sherika
    Purdue, Lynette
    Holmes, Lewis B.
    Momper, Jeremiah D.
    Shapiro, Roger L.
    Thoofer, Navdeep K.
    Rooney, James F.
    Frenkel, Lisa M.
    Amico, K. Rivet
    Chinula, Lameck
    Currier, Judith
    LANCET, 2021, 397 (10281): : 1276 - 1292
  • [2] The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz
    Asif, Sumbul
    Baxevanidi, Evangelia
    Hill, Andrew
    Venter, Willem Daniel Francois
    Fairlie, Lee
    Masenya, Masebole
    Serenata, Celicia
    Sokhela, Simiso
    Chandiwana, Nomathemba
    AIDS, 2021, 35 : S117 - S125
  • [3] Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
    Venter, Willem D. F.
    Sokhela, Simiso
    Simmons, Bryony
    Moorhouse, Michelle
    Fairlie, Lee
    Mashabane, Nkuli
    Serenata, Celicia
    Akpomiemie, Godspower
    Masenya, Masebole
    Qavi, Ambar
    Chandiwana, Nomathemba
    McCann, Kaitlyn
    Norris, Shane
    Chersich, Matthew
    Maartens, Gary
    Lalla-Edward, Samanta
    Vos, Alinda
    Clayden, Polly
    Abrams, Elaine
    Arulappan, Natasha
    Hill, Andrew
    LANCET HIV, 2020, 7 (10): : E666 - E676
  • [4] An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate
    McGowan, Ian M.
    Kunjara Na Ayudhya, Ratiya Pamela
    Brand, Rhonda M.
    Marzinke, Mark A.
    Hendrix, Craig W.
    Johnson, Sherri
    Piper, Jeanna
    Holtz, Timothy H.
    Curlin, Marcel E.
    Chitwarakorn, Anupong
    Raengsakulrach, Boonyos
    Doncel, Gustavo
    Schwartz, Jill L.
    Rooney, James F.
    Cranston, Ross D.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (04) : 279 - 287
  • [5] Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
    Cohen, Calvin
    Elion, Richard
    Ruane, Peter
    Shamblaw, David
    DeJesus, Edwin
    Rashbaum, Bruce
    Chuck, Steven L.
    Yale, Kitty
    Liu, Hui C.
    Warren, David R.
    Ramanathan, Srinivasan
    Kearney, Brian P.
    AIDS, 2011, 25 (06) : F7 - F12
  • [6] Renal outcomes with efavirenz plus tenofovir disoproxil fumarate/emtricitabine versus other tenofovir disoproxil fumarate-containing antiretroviral regimens among HIV-infected veterans: a national study
    LaFleur, J.
    Bress, A.
    Esker, S.
    Crook, J.
    Nyman, H.
    Bedimo, R.
    Tebas, P.
    Rosenblatt, L.
    ANTIVIRAL THERAPY, 2016, 21 : A60 - A60
  • [7] Associations with HIV-related symptoms and weight change after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide
    Lowman, E.
    Hardigan, P.
    Unger, N.
    Lee, N.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 75 - 75
  • [8] The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
    Wang, Huilian
    Lu, Xi
    Yang, Xudong
    Xu, Nan
    MEDICINE, 2016, 95 (41)
  • [9] Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection
    Bedimo, Roger
    Rosenblatt, Lisa
    Myers, Joel
    HIV CLINICAL TRIALS, 2016, 17 (06): : 246 - 266
  • [10] Concomitant Administration of BILR 355/r with Emtricitabine/Tenofovir Disoproxil Fumarate Increases Exposure to Emtricitabine and Tenofovir: A Randomized, Open-Label, Prospective Study
    Huang, Fenglei
    Scholl, Paul
    Huang, David B.
    MacGregor, Thomas R.
    Taub, Mitchell E.
    Vinisko, Richard
    Castles, Mark A.
    Robinson, Patrick
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 108 (03) : 163 - 170
12345